The ICMR Director-General Balram Bhargava had said that molnupiravir has major safety concerns and has not been included in the national pr...

Generic molnupiravir will increase access in India and other low- and middle-income countries (LMICs), while simplifying current supply cha...

Molnupiravir has been given emergency use authorisation by the Drug Controller General of India (DCGI) for treatment of adult COVID-19 pati...

Merck Sharp & Dohme (MSD) on Friday said its COVID antiviral molnupiravir has cut the risk of hospitalization or death in Phase 3 clinical ...

Molnupiravir is for treatment of adult patients hospitalised with COVID-19, under certain conditions, a press release from the city-based d...

The full treatment of Molulife (brand name) is expected to cost ₹1,400, RC Juneja, chairman of Mankind Pharma, told ET. The brand is expect...

Molnupiravir is the first COVID-19 drug authorised by the Drugs Controller General of India (DCGI) for the treatment of COVID-19 infection ...

Drug maker Cipla said it will soon make molnupiravir capsules available at all leading pharmacies and Covid treatment centers across the co...

Torrent Pharmaceuticals on Tuesday said it will launch MSD and Ridgeback's molnupiravir under the brand name Molnutor in India for the trea...

The USFDA also said molnupiravir should be given to those for whom alternative Covid-19 treatment options authorised by it are not accessib...

The USFDA also said the drug should be given for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or cl...

The analysis of latest data on efficacy is much less than the previous interim analysis announced by the company which was based on data fr...

The company said the Drugs Controller General of India (DCGI) is currently reviewing clinical data of molnupiravir for the treatment of COV...

Natco has conducted Phase III trials of molnupiravir and submitted the trial results to the drug regulator this month. "We have submitted p...

Under the terms of the agreement, MPP will be permitted to further license non-exclusive sub-licences to manufacturers and diversify the ma...

One promising drug that could improve things is molnupiravir, an antiviral that's moving into the final stages of testing in humans. Resear...

Molnupiravir was originally developed to treat influenza before US-based Merck initiated research to repurpose drug for use against SARS-Co...